How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Dapagliflozin with insulin for treating type 1 diabetes

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about dapagliflozin

Marketing authorisation

Dapagliflozin (Forxiga, AstraZeneca) is indicated for the treatment of 'type 1 diabetes mellitus as an adjunct to insulin in patients with a BMI ≥27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy'. Dapagliflozin should not be started in people with type 1 diabetes with a low insulin need. During treatment with dapagliflozin, insulin therapy should be continuously optimised to prevent ketosis and diabetic ketoacidosis, and the insulin dose should only be reduced to avoid hypoglycaemia. This treatment should only be started and supervised by specialist doctors. Patients should be able and committed to control ketone levels in their body. They should be educated about risk factors for diabetic ketoacidosis and how to recognise its signs and symptoms.

Dosage in the marketing authorisation

Administered orally at a dosage of 5 mg once daily.

Price

The list price of dapagliflozin is £36.59 for 28 tablets (excluding VAT; British National Formulary online, accessed April 2019). The treatment cost at list price is £477.30 per year. Costs may vary in different settings because of negotiated procurement discounts.